CCR7 and neoplasm: Tumor-infiltrating T cells are predominantly antigen experienced CD45− CCR7− effector/memory T cells (74.7% of CD45+CD3+ lymphocytic cells in tumor tissue compared to 30.2% and 26% in PBMCs of CRC patients and healthy controls respectively, p<0,005, Fig. 5A).